NDASUBCUTANEOUSSOLUTION
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
LANREOTIDE ACETATE (lanreotide acetate) by Gen Pharmaceuticals is lanreotide, the active component of lanreotide injection, is an octapeptide analog of natural somatostatin. First approved in 2021.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lanreotide Acetate is a somatostatin analog administered via subcutaneous injection in solution form. It mimics natural somatostatin to treat neuroendocrine tumors and acromegaly by inhibiting hormone secretion. The drug was approved in December 2021 and operates through octapeptide mechanisms similar to endogenous somatostatin.
$7MPart D
PeakProduct is in peak lifecycle stage with $7M Part D spending; commercial team is likely stable or optimizing market penetration in a niche indication.
Mechanism of Action
Lanreotide, the active component of Lanreotide Injection, is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Lanreotide Acetate careers focus on specialty/niche market management given the rare disease indication profile and subcutaneous delivery model. Professionals on this team should expect deep expertise in neuroendocrine tumor and acromegaly patient management, healthcare provider relationships, and reimbursement navigation.
Brand ManagerMedical Science Liaison (MSL)
Worked on LANREOTIDE ACETATE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.